Business Wire

ABB: Q2 2022 Results

21.7.2022 07:46:00 EEST | Business Wire | Press release

Share

Ad hoc Announcement pursuant to Art. 53 Listing Rules of SIX Swiss Exchange

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220720005866/en/

  • Orders $8.8 billion, +10%; comparable1 +20%
  • Revenues $7.3 billion, -3%; comparable +6%
  • Income from operations $587 million; margin 8.1%
  • Operational EBITA1 $1,136 million; margin1 15.5%
  • Basic EPS $0.20; -47%2
  • Cash flow from operating activities $382 million

KEY FIGURES

 

 

 

 

 

 

 

 

 

 

 

CHANGE

 

 

CHANGE

($ millions, unless otherwise indicated)

Q2 2022

Q2 2021

US$

Comparable1

H1 2022

H1 2021

US$

Comparable1

Orders

8,807

7,989

10%

20%

18,180

15,745

15%

24%

Revenues

7,251

7,449

-3%

6%

14,216

14,350

-1%

7%

Gross Profit

2,290

2,508

-9%

 

4,571

4,776

-4%

 

as % of revenues

31.6%

33.7%

-2.1 pts

 

32.2%

33.3%

-1.1 pts

 

Income from operations

587

1,094

-46%

 

1,444

1,891

-24%

 

Operational EBITA1

1,136

1,113

2%

9% 3

2,133

2,072

3%

9% 3

as % of operational revenues1

15.5%

15.0%

+0.5 pts

 

14.9%

14.4%

+0.5 pts

 

Income from continuing operations, net of tax

406

789

-49%

 

1,049

1,340

-22%

 

Net income attributable to ABB

379

752

-50%

 

983

1,254

-22%

 

Basic earnings per share ($)

0.20

0.37

-47%2

 

0.51

0.62

-18%2

 

Cash flow from operating activities4

382

663

-42%

 

(191)

1,206

n.a.

 

Cash flow from operating activities in continuing operations

385

663

-42%

 

(179)

1,186

-115%

 

 

 

 

 

 

 

 

 

 

 

1

For a reconciliation of non-GAAP measures, see “supplemental reconciliations and definitions” in the attached Q2 2022 Financial Information.

2

EPS growth rates are computed using unrounded amounts.

3

Constant currency (not adjusted for portfolio changes).

4

Amount represents total for both continuing and discontinued operations.

“I am pleased with our performance and that we have taken yet another step toward our long-term margin target. I am also delighted that we are moving ahead with the spin-off of Accelleron and its planned listing in Switzerland.”

Björn Rosengren, CEO

CEO summary

Overall, I am pleased with how the teams delivered strong order growth as well as a margin in line with our long-term target. This was achieved despite the pressure from a tight supply chain, Covid-enforced lockdowns in China and the inflationary environment. Cash flow came in higher than in the first quarter, and I expect a good momentum in the second half of the year.

We achieved a strong order growth of 10% (20% comparable) and we saw a positive development in all major customer segments. While changes in exchange rates weighed on the total, comparable orders increased at a double-digit rate in all regions. With all business areas in double-digit growth, order intake amounted to $8,807 million and a record-high order backlog of $19.5 billion.

In total, revenues declined by 3% (up 6% comparable), year-on-year. Negative impact from changes in exchange rates and portfolio changes outweighed the positives of strong price execution and increased volumes, with the latter somewhat held back by the strained supply chain. Comparable revenues increased in all business areas except for Robotics & Discrete Automation which together with the Distribution Solutions division in Electrification, are where customer deliveries were materially slowed by component shortages. Overall, the supply chain constraints slightly eased compared with the previous quarter, however we saw temporary pressure on customer deliveries in China where lockdowns slowed down logistics somewhat more than expected. We anticipate further easing of component supply in the coming quarters.

I am pleased that we managed to improve the Operational EBITA margin to 15.5%. Notably, our teams successfully offset inflationary effects such as input costs and freight through strong pricing execution and higher volumes. Process Automation noted a sharp 180 basis point improvement to its margin, year-on-year. I am also pleased with the performance levels in Electrification and Motion, although margins declined from last year’s high levels. Robotics & Discrete Automation is the area with operational underperformance, triggered by customer deliveries materially hampered by lockdowns in China and semiconductor shortages. Additionally, results were supported by lower than anticipated costs in Corporate and Other including a positive margin impact of approximately 60 basis points related to the exit of a legacy project and a real estate sale which came through sooner than expected.

Looking at Income from operations, it included items impacting comparability of approximately $250 million.These include the earlier mentioned charge of $195 million triggered by us exiting the largest legacy project exposure in non-core operations, namely the full-train retrofit business. It also includes the financial impact of our decision to exit the Russian market, triggered by the ongoing war in Ukraine and impact of related international sanctions. We have started the process of winding down the remaining activities in Russia. This triggered a charge of $57 million, of which $23 million will impact cash flow in the third quarter.

The balance sheet is robust, although year-on-year the cash flow from operating activities in continuing operations declined to $385 million, mainly on a higher build-up of net working capital. That said, we have continued to execute on our share buyback program, and just after the close of the second quarter we successfully delivered on our promise to return to shareholders the remaining $1.2 billion - out of the total of $7.8 billion - from the Power Grids proceeds. We will now continue with the execution of our ongoing buyback program of up to $3 billion.

On the back of the volatile financial markets, we decided to postpone the planned IPO of our E-mobility business. We will monitor the market conditions and are fully committed to proceed with a listing on the SIX Swiss Exchange as and when market conditions are constructive. Meanwhile, building on the earlier seed stage investment three years ago, the E-mobility team has agreed to acquire a controlling interest in Numocity, a leading digital platform for EV charging in India. This deal allows E-mobility to leverage on the regional opportunity from increasing demand for charging solutions for two and three-wheelers, cars and light commercial vehicles. After the close of the second quarter, we decided to spin off the Accelleron business (Turbocharging) with a planned listing on SIX Swiss Exchange on October 3, subject to approval by the Extraordinary General Meeting. I am pleased about this as it allows for shareholders to realize the full value of Accelleron while allowing ABB to focus on its core areas of electrification and automation.

Björn Rosengren
CEO

Outlook

In the third quarter of 2022, we anticipate double-digit comparable revenue growth and the Operational EBITA margin to sequentially improve, excluding the 60 basis points positive impact from special items in the second quarter.

In full-year 2022, we expect a steady margin improvement towards the 2023 target of at least 15%, supported by increased efficiency as we fully incorporate the decentralized operating model and performance culture in all our divisions. Furthermore, we expect support from a positive market momentum and our strong order backlog.

The complete press release including the appendices is available at www.abb.com/news.

ABB (ABBN: SIX Swiss Ex) is a leading global technology company that energizes the transformation of society and industry to achieve a more productive, sustainable future. By connecting software to its electrification, robotics, automation and motion portfolio, ABB pushes the boundaries of technology to drive performance to new levels. With a history of excellence stretching back more than 130 years, ABB’s success is driven by about 105,000 talented employees in over 100 countries.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

ABB Ltd
Affolternstrasse 44
8050 Zurich
Switzerland

Media Relations
Phone: +41 43 317 71 11
Email: media.relations@ch.abb.com

Investor Relations
Phone: +41 43 317 71 11
Email: investor.relations@ch.abb.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OdysseyRe Announces New Co-Chief Underwriting Officers for EMEA18.5.2026 10:00:00 EEST | Press release

Odyssey Reinsurance Company (OdysseyRe) today announced the appointments of Tegwen Gromellon and Anne-Claire Serres as co-chief underwriting officers of its EMEA division, effective July 1. They succeed longtime Chief Underwriting Officer, Gaël Le Païh, who is retiring later this year following 36 years with the Company. Based in Paris, Serres joined OdysseyRe in 2018 as the market director for France and will lead the division’s business across France, Africa and the Middle East. Gromellon, who joined OdysseyRe in 2004, has served as market director for Germany, Austria, Benelux and Switzerland since 2019. He will take the lead for the rest of Europe, including the relationship with the Company’s representative office in Stockholm for the Nordic markets and across Turkey. “We are delighted to appoint both Tegwen and Anne-Claire to these important leadership positions,” said Isabelle Dubots-Lafitte, chief executive officer of EMEA for OdysseyRe. “These appointments recognize their sign

Prokarium Reports Positive Interim Data from Phase 1/1b PARADIGM-1 trial of ZH9 in NMIBC patients, Demonstrating Excellent Safety and Encouraging Early Efficacy18.5.2026 10:00:00 EEST | Press release

Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapies for the treatment of solid tumours, today announced safety and antitumour efficacy results from an interim review of the ongoing Phase 1/1b PARADIGM-1 trial of ZH9 in non-muscle invasive bladder cancer (NMIBC) patients. These data were shared via an oral podium presentation at the American Urology Association (AUA26) Annual Meeting. Prokarium CMO, Dr Josefin-Beate Holz said “These data demonstrate ZH9 as a universally applicable treatment for patients. As the treatment is very well tolerated and is showing impactful outcomes for early and BCG-non-responsive patients alike, it opens up the potential for ZH9 to be a transformative bladder saving treatment.” "There is a clear and urgent need to move beyond BCG. The current treatment burden—requiring up to 18 catheterisations in the first year— detrimentally impacts real-world compliance and patient outcomes," said Ibs Mahmood, CEO of Prokarium. "Pat

Arboris Capital Selects ROYC to Expand Private Markets Capabilities on CapGain Platform18.5.2026 10:00:00 EEST | Press release

Arboris Capital Limited (“Arboris”), a DIFC-based firm arranging alternative investments, authorised by the Dubai Financial Services Authority (DFSA), today announced that it has selected ROYC AB (“ROYC”), a private markets technology and infrastructure provider, to support the continued development of its private markets offering through its platform, CapGain. In its ongoing efforts to expand its private markets capabilities across the Middle East, Arboris has undertaken a strategic review of how to further scale its offering while maintaining the integrity of its existing platform. As a result, Arboris has chosen to integrate ROYC’s fund access, sourcing, and structuring capabilities into CapGain, complementing its existing infrastructure. CapGain is Arboris’s proprietary investment platform, purpose-built to facilitate access between international private market opportunities and Professional Investors in the region. CapGain provides fully digital investor onboarding and KYC, a secu

LogicMonitor and Deutsche Telekom Expand Partnership Across Europe18.5.2026 10:00:00 EEST | Press release

LogicMonitor®, the AI-first platform for Autonomous IT, today announced the expanded availability of its platform within Deutsche Telekom’s managed services portfolio across selected European markets, including DACH, Benelux, and the Nordics. The expansion builds on operational use of LogicMonitor in the United Kingdom since 2023, where it has supported Deutsche Telekom’s service teams in improving visibility across network, cloud, and hybrid infrastructure environments. Experience gained from these deployments is now informing broader service enablement across additional European markets. As enterprise IT environments grow more complex, organisations require more than visibility—they need predictive resilience. Through defined use cases, LogicMonitor complements Deutsche Telekom’s existing service management, monitoring, and security tooling, helping teams anticipate, detect, and resolve issues before they impact business operations. In the United Kingdom, the partnership has delivere

VahatiCor Appoints Harry D. Rowland, Ph.D., as Chief Executive Officer18.5.2026 09:00:00 EEST | Press release

VahatiCor, Inc., a medtech company developing interventional therapies for Coronary Microvascular Dysfunction (CMD), announced today the appointment of Harry D. Rowland, Ph.D., as Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260517830314/en/ VahatiCor CEO, Harry D. Rowland, Ph.D. Rowland previously served as Chief Executive Officer and President of Endotronix, where he led the development and commercialization of the Cordella™ Pulmonary Artery Sensor and Heart Failure System. Under his leadership, Endotronix raised over $150 million and grew to more than 150 employees. He also oversaw the PROACTIVE-HF pivotal trial from execution through FDA premarket approval and commercial launch. Following its acquisition by Edwards Lifesciences in 2024, Rowland stayed on to support key CMS national coverage and CE Mark milestones. "Harry has led a medical company through this arc before. He took Endotronix from

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye